(R)-(-)-3,4-dihydro-3-methylisoquinolin-1-(2H)-one | 61768-98-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: (R)-(-)-3,4-dihydro-3-methylisoquinolin-1-(2H)-one
• 英文别名: (-)-3-methyl-3,4-dihydroquinolone-1；1(2H)-Isoquinolinone, 3,4-dihydro-3-methyl-, (R)-；(3R)-3-methyl-3,4-dihydro-2H-isoquinolin-1-one
• CAS: 61768-98-7
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: BWWCBNZSMWMIKH-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (R)-(-)-3,4-dihydro-3-methylisoquinolin-1-(2H)-one 在 盐酸 、 硼烷四氢呋喃络合物 、 硫酸 、 potassium nitrate 作用下， 反应 24.0h， 生成 (R)-3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline
  参考文献：
  名称：

  3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines Display Remarkable Potency and Selectivity as Inhibitors of Phenylethanolamine N-Methyltransferase versus the α₂-Adrenoceptor^1a

  摘要：

  3-Hydroxymethyl-1,2,3,4-tetrahydroisoquinoline (4) is a more selective inhibitor (PNMT K-i = 1.1 mu M, alpha(2) K-i = 6.6 mu M, selectivity (alpha(2) K-i/PNMT K-i) = 6.0) of phenylethanolamine N-methyltransferase (PNMT, EC 2.1.1.28), with respect to its az-adrenoceptor affinity, than is 3-methyl-1,2,3,4-tetrahydroisoquinoline (2; PNMT K-i = 2.1 mu M, alpha 2 K-i = 0.76 mu M, selectivity = 0.36) or 1,2,3,4-tetrahydroisoquinoline (1, THIQ; PNMT K-i = 9.7 mu M, alpha 2 K-i = 0.35 mu M, selectivity = 0.036). Evaluation of the O-methyl ether derivative of 4 suggested that the 3-hydroxymethyl substituent might be involved in a hydrogen-bond donor-type of interaction at a sterically compact region in the PNMT active site. The directionality of the steric bulk tolerance at both the PNMT active site and the alpha(2)-adrenoceptor appears to be the same. Since the presence of a hydrophilic electron-withdrawing substituent (such as NO2, SO2CH3, or SO2NH2) at the 7-position of THIQ reduced the binding affinity toward the alpha(2)-adrenoceptor, we investigated the combination of both a hydrophilic electron-withdrawing 7-substituent and a S-alkyl substituent on a THIQ nucleus. A synergistic effect in increasing the PNMT-inhibitory potency of the THIQ nucleus and reducing the affinity toward the alpha(2)-adrenoceptor was observed with this 3,7-disubstitution. Remarkably, 7-aminosulfonyl-3-hydroxymethyl-THIQ (12; PNMT K-i = 0.34 mu M, alpha 2 K-i = 1400 mu M, selectivity = 4100) displayed a 23-680-fold enhanced selectivity over the parent compounds 27 (SK&F 29661; PNMT K-i = 0.55 mu M, alpha 2 K-i = 100 mu M, selectivity = 180) and 4 (selectivity = 6.0) and is thus the most selective PNMT inhibitor yet reported.

  DOI：

  10.1021/jm9807252
• 作为产物：
  描述：

  (-)-(R)-methylbenzylacetohydroxamic acid 生成 (R)-(-)-3,4-dihydro-3-methylisoquinolin-1-(2H)-one
  参考文献：
  名称：

  POTAPOV, V. M.;DEMYANOVICH, V. M.;VENDROVA, O. E.;XLEBNIKOV, V. A., XIMIYA GETEROTSIKL. SOEDIN., 1983, N 5, 655-660

  摘要：

  DOI：

文献信息

• ALICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1970373A1

  公开（公告）日：2008-09-17

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下是该公式表示的脂环杂环化合物或其药用可接受盐： 其中环A是杂环，环B是碳环，杂环等，P1和P2是CH或N，q和r为0至2，X为-NH-，-O-，-CH2-等，Y为-CH2-，-CO-，-SO2-等，Z为-CO-，-SO2-等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基， 可用作CCR4功能的控制剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• Novel pyrrolidine compound and a process for preparing the same
  申请人：Moritani Yasunori

  公开号：US20070167440A1

  公开（公告）日：2007-07-19

  The present invention relates to a novel pyrrolidine compound, which has a potent antagonistic activity against central cannabinoid (CB1) receptor, having the formula [I]: wherein each of R 1 and R 2 is (A) optionally substituted aryl (or heteroaryl) group, or (B) both of the groups combine to form a group of the formula: one of R 3 and R 4 is hydrogen and another is hydrogen, hydroxyl, hydroxyalkyl, etc., or both of R 3 and R 4 combine to form oxo group, R 5 is hydrogen or alkyl, Y is single bond, oxygen atom or a group of the formula: —N(R 7 )—, R 6 is optionally substituted hydrocarbon group or optionally substituted cyclic group, R 7 is alkyl or alkyloxycarbonylalkyl, provided that R 6 is not 4-amino-5-chloro-2-methoxyphenyl group when Y is single bond and one of the R 3 and R 4 is hydrogen and another is hydroxymethyl, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种新型吡咯烷化合物，其具有对中枢大麻素（CB1）受体的强烈拮抗活性，其化学式为[I]：其中，R1和R2中的每一个是（A）可选取的取代芳基（或杂环芳基）基团，或者（B）两个基团结合形成式的基团：R3和R4中的一个是氢，另一个是氢、羟基、羟基烷基等，或者R3和R4结合形成氧代基团，R5是氢或烷基，Y是单键、氧原子或式的基团：—N(R7)—，R6是可选取的取代的碳氢基团或可选取的取代的环状基团，R7是烷基或烷氧羰基烷基，但当Y为单键且R3和R4中的一个为氢，另一个为羟甲基时，R6不是4-氨基-5-氯-2-甲氧基苯基团，或其药学上可接受的盐。
• Alicyclic Heterocyclic Compound
  申请人：Furukubo Shigeru

  公开号：US20090182140A1

  公开（公告）日：2009-07-16

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P 1 and P 2 are CH or N, q and r are 0 to 2, X is —NH—, —O—, —CH 2 —, etc., Y is —CH 2 —, —CO—, —SO 2 —, etc., Z is —CO—, —SO 2 —, etc., and R 3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR 4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下式子所示的脂环杂环化合物或其药学上可接受的盐： 其中环A为杂环，环B为碳环，杂环等，P1和P2为CH或N，q和r为0至2，X为—NH—，—O—，—CH2—等，Y为—CH2—，—CO—，—SO2—等，Z为—CO—，—SO2—等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基，用作CCR4功能调节剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• Potapov, V. M.; Dem'yanovich, V. M.; Vendrova, O. E., Doklady Chemistry, 1981, vol. 258, p. 221 - 223
  作者：Potapov, V. M.、Dem'yanovich, V. M.、Vendrova, O. E.、Khlebnikov, V. A.

  DOI：——

  日期：——
• NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS
  申请人：Eli Lilly and Company

  公开号：EP2917194B1

  公开（公告）日：2017-09-27